Shenlingcao Oral Liquid for Patients with Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy after Radical Resection: A Multicenter Randomized Controlled Trial
Yanmei Liu,Xiaochao Luo,Jiali Liu,Yu Ma,Jing Tan,Wen Wang,Jian Hu,Xiangning Fu,Lin Xu,Fenglei Yu,Shidong Xu,Haitao Ma,Xiuyi Yu,Qingjun You,Zhiqiang Wang,Ling Li,Xun Zhang,Xin Sun
DOI: https://doi.org/10.1016/j.phymed.2023.154723
IF: 6.656
2023-01-01
Phytomedicine
Abstract:BACKGROUND:Low quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy after radical resection is a major global health issue. High-quality evidence for the effectiveness of Shenlingcao oral liquid (SOL) as a complementary treatment in this patients is lacking at present.PURPOSE:To determine whether complementary SOL treatment in NSCLC patients receiving adjuvant chemotherapy would yield greater improvements in QoL than chemotherapy alone.STUDY DESIGN:We conducted a multicenter, randomized controlled trial of stages IIA-IIIA NSCLC patients undergoing adjuvant chemotherapy in seven hospitals.METHODS:Using stratified blocks, participants were randomized in a 1:1 ratio to receive SOL combined with conventional chemotherapy or conventional chemotherapy alone. The primary outcome was the change in global QoL from baseline to the fourth chemotherapy cycle, and intention-to-treat analysis was applied with a mixed-effect model. Secondary outcomes were functional QoL, symptoms, and performance status scores at the 6-month follow-up. Missing data were handled with multiple imputation and a pattern-mixture model.RESULTS:Among 516 randomized patients, 446 (86.43%) completed the study. After the fourth chemotherapy cycle, in comparison with the control group, patients receiving SOL showed a lower reduction in mean global QoL (-2.76 vs. -14.11; mean difference [MD], 11.34; 95% confidence interval [CI], 8.28 to 14.41), greater improvement in physical function (MD, 11.61; 95% CI, 8.57 to 14.65), role function (MD, 10.15; 95% CI, 5.75 to 14.54), and emotional function (MD, 4.71; 95% CI, 1.85 to 7.57), and greater improvements in lung cancer-related symptoms (e.g., fatigue, nausea/vomiting, and appetite loss) and performance status during the 6-month follow-up period (treatment main effect, p < 0.05).CONCLUSION:SOL treatment for NSCLC patients receiving adjuvant chemotherapy can significantly improve QoL and performance status within 6 months after radical resection.TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT03712969.